Ryvu Therapeutics SA

Research Ryvu Therapeutics SA (RVU) on Bullrun: market cap PLN 434.66M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerRVU
ExchangeWAR
CountryPoland
SectorHealthcare
IndustryBiotechnology
CurrencyPLN
Market capPLN 434.66M
Financial periodQ1 2026
RevenuePLN 16.95M
Net income-PLN 12.65M
Free cash flow-PLN 23.53M
Gross margin75.6%

Valuation Snapshot

latest market cap is PLN 434.66M.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	PLN 62.25M	-PLN 101.23M	-PLN 121.57M	76.2%	n/a	PLN 55.55M	PLN 71.72M	PLN 53.83M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-24	PLN 434.66M	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 PLN.

About Ryvu Therapeutics SA

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis.

Related stock research

Poland stocks Poland Healthcare stocks A-Z stock index

Other Healthcare stocks

ONCOARENDI THERAP ZY-01 (1B1) Mabion SA (272) BIOMED-LUBLIN WYT.SUR. (6NQ) Nanogroup SA (NNG) PURE BIOLOGICS ZY -10 (PQB) PolTREG S.A. (PTG) Urteste SA (URT) BIOCELTIX S.A. ZY -10 (XI3) VOXEL SA ZY 1 (0NX) SELVITA S.A. SER.B ZY-80 (787) NEUCA S.A. (7HD) Diagnostyka S.A. (7JS)

Frequently asked questions

What is Ryvu Therapeutics SA's market cap?

Ryvu Therapeutics SA's market capitalization is PLN 434.66M.